Influenza and Other Respiratory Viruses

Scope & Guideline

Pioneering studies in respiratory virus management.

Introduction

Immerse yourself in the scholarly insights of Influenza and Other Respiratory Viruses with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1750-2640
PublisherWILEY
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 2007 to 2024
AbbreviationINFLUENZA OTHER RESP / Influenza Other Respir. Viruses
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Influenza and Other Respiratory Viruses' serves as a pivotal platform for advancing the understanding of respiratory viruses, particularly focusing on influenza and SARS-CoV-2, among others. Its aims encompass a broad range of studies that address the epidemiology, clinical impact, and vaccine effectiveness of respiratory viruses, while also exploring novel diagnostic and therapeutic approaches.
  1. Epidemiology of Respiratory Viruses:
    Research focused on the patterns, causes, and effects of respiratory viruses, including seasonal trends and outbreak dynamics across various populations and geographical locations.
  2. Vaccine Effectiveness and Immunology:
    Investigating the effectiveness of vaccines against respiratory viruses, including influenza and SARS-CoV-2, as well as the immunological responses elicited by these vaccines in different demographic groups.
  3. Clinical Outcomes and Disease Burden:
    Studies assessing the clinical implications of infections caused by respiratory viruses, including hospitalization rates, morbidity, mortality, and overall health impact on affected populations.
  4. Diagnostic Methods and Innovations:
    Exploration of novel diagnostic techniques and technologies for the identification and management of respiratory infections, enhancing timely clinical decisions.
  5. Antiviral Treatments and Therapeutic Strategies:
    Research into the efficacy and safety of antiviral medications and other therapeutic interventions aimed at treating infections caused by respiratory viruses.
  6. Surveillance and Public Health:
    Efforts to enhance surveillance systems for respiratory viruses, providing insights into transmission dynamics and informing public health responses.
The journal has shown a dynamic evolution in its research focus, particularly in response to the COVID-19 pandemic. This section outlines the trending and emerging themes that have gained traction in recent publications, highlighting their relevance in current public health discourse.
  1. COVID-19 Vaccine Efficacy and Safety:
    A significant increase in studies evaluating the effectiveness and safety of various COVID-19 vaccines, reflecting ongoing global vaccination efforts and the need for continuous assessment of vaccine performance.
  2. Long COVID and Post-Viral Syndromes:
    Emerging research focusing on the long-term effects of COVID-19, including 'Long COVID' symptoms, is gaining prominence as the medical community seeks to understand and address these complex health issues.
  3. Impact of Non-Pharmaceutical Interventions:
    Studies examining the effects of non-pharmaceutical interventions (NPIs) on respiratory virus transmission patterns, particularly during the COVID-19 pandemic, are increasingly relevant for future public health strategies.
  4. Variants of Concern and Their Epidemiology:
    Research centered on the epidemiology and clinical implications of SARS-CoV-2 variants, particularly Omicron and its sublineages, has surged as understanding these variants is critical for managing future outbreaks.
  5. Artificial Intelligence in Diagnostics:
    The integration of artificial intelligence and machine learning in the diagnosis and management of respiratory viruses, enhancing speed and accuracy in clinical settings, is an emerging trend.

Declining or Waning

While the journal maintains a robust focus on various aspects of respiratory viruses, certain themes have shown a decline in prominence over recent years. This section identifies these waning scopes, reflecting shifts in research priorities and emerging health challenges.
  1. Non-Influenza Respiratory Viruses:
    Research specifically targeting non-influenza respiratory viruses, while still relevant, appears to be receiving comparatively less attention as the focus has shifted towards COVID-19 and its variants.
  2. Historical Analysis of Past Pandemics:
    Studies examining the historical impact of past influenza pandemics are less frequently published, likely overshadowed by contemporary issues related to COVID-19.
  3. Animal Models for Viral Research:
    While still important, the use of animal models in studying respiratory viruses may be declining as more emphasis is placed on human epidemiological studies and clinical trials.
  4. Influenza D Virus Research:
    Research on influenza D virus has waned, possibly due to its relatively low impact on human health compared to other respiratory viruses like influenza A/B and SARS-CoV-2.
  5. Longitudinal Studies of Seasonal Variability:
    Long-term studies tracking seasonal variability of respiratory viruses have decreased, as immediate responses to emerging threats like COVID-19 take precedence.

Similar Journals

LUNG

Exploring the complexities of lung diseases for better patient outcomes.
Publisher: SPRINGERISSN: 0341-2040Frequency: 6 issues/year

LUNG is a prestigious academic journal that has been a cornerstone in the field of Pulmonary and Respiratory Medicine since its inception in 1959. Published by SPRINGER, the journal holds an impressive Q1 ranking in its category for 2023, reflecting its commitment to disseminating high-quality research and advancing clinical practices in respiratory health. With a Scopus rank of 24 out of 155 in its field, representing the top 16% of journals, LUNG continues to serve as a vital platform for researchers, clinicians, and students who are dedicated to addressing the complexities of lung diseases. Although currently not an open-access journal, LUNG offers valuable insights and significant contributions to the understanding of respiratory conditions, ensuring that its readership stays at the forefront of medical advancements. Researchers and professionals are encouraged to submit their work and engage with a thriving academic community that is passionate about improving patient outcomes in pulmonary health.

Zeitschrift fur Pneumologie

Pioneering Discoveries in Respiratory Medicine
Publisher: SPRINGER HEIDELBERGISSN: 2731-7404Frequency: 6 issues/year

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

Egyptian Journal of Chest Diseases and Tuberculosis

Advancing respiratory health through open access research.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0422-7638Frequency: 4 issues/year

The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

THORAX

Advancing pulmonary knowledge, one study at a time.
Publisher: BMJ PUBLISHING GROUPISSN: 0040-6376Frequency: 12 issues/year

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

Respiratory Investigation

Transforming insights into impactful respiratory solutions.
Publisher: ELSEVIERISSN: 2212-5345Frequency: 6 issues/year

Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.

Pulmonary Medicine

Elevating Knowledge in Respiratory Research
Publisher: HINDAWI LTDISSN: 2090-1836Frequency: 1 issue/year

Pulmonary Medicine, published by HINDAWI LTD, stands as a prestigious open-access journal since 2010, dedicated to advancing the field of pulmonary and respiratory medicine. Located in Egypt, this journal is indexed with an ISSN of 2090-1836 and an E-ISSN of 2090-1844, and it has attained a commendable Q2 ranking in both the miscellaneous medicine and pulmonary health categories, indicative of its significant impact and quality. With an impressive Scopus ranking of #15 out of 155 in the pulmonary and respiratory medicine category, the journal is positioned in the 90th percentile, highlighting its relevance and contribution to ongoing research. The journal aims to publish high-quality original research, reviews, and clinical studies that address pressing issues in pulmonary health, making it a vital resource for researchers, clinicians, and students seeking to enhance their understanding and practice in respiratory medicine. By embracing an open-access model, Pulmonary Medicine provides a platform for disseminating knowledge, fostering collaboration, and driving innovation within the global scientific community.

Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine

Transforming Insights into Impact for Patient Care
Publisher: SAGE PUBLICATIONS LTDISSN: 1179-5484Frequency: 1 issue/year

Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine, published by SAGE Publications Ltd, stands as a vital resource in the fields of Cardiology and Pulmonary Medicine, underscored by its Q3 quartile rankings in both areas for 2023. Established in 2007 as an open-access journal, it facilitates the dissemination of cutting-edge research and observations from the international scientific community. With an ISSN of 1179-5484, the journal has garnered recognition for its contributions to clinical medicine, particularly covering topics of circulatory, respiratory, and pulmonary health. The journal not only aims to bridge the gap between research and clinical practice but also to serve as a platform for innovative ideas and collaborations among researchers, healthcare professionals, and trainees. By offering unrestricted access to its articles, Clinical Medicine Insights ensures that vital knowledge reaches a broad audience, ultimately fostering advancements in medical science and patient care.

Therapeutic Advances in Respiratory Disease

Advancing Knowledge in Respiratory Health
Publisher: SAGE PUBLICATIONS LTDISSN: 1753-4658Frequency: 1 issue/year

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

Annals of the American Thoracic Society

Connecting researchers and clinicians for a healthier tomorrow.
Publisher: AMER THORACIC SOCISSN: 1546-3222Frequency: 12 issues/year

Annals of the American Thoracic Society is a premier journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by the American Thoracic Society, this journal offers an invaluable platform for researchers and clinicians to disseminate cutting-edge research, clinical insights, and innovative methodologies. With an impressive impact factor and ranked in the top Q1 category of its field (2023) and within the top 20 of 155 according to Scopus rankings, it is positioned as a leading force in shaping clinical practice and research directions. The journal's convergence years from 2013 to 2024 indicate a commitment to providing timely and relevant content at the forefront of pulmonary health. While not an open-access journal, it ensures broad accessibility to its significant contributions in respiratory medicine, making it an essential resource for professionals, researchers, and students alike endeavoring to deepen their understanding and improve outcomes in thoracic health.

Expert Review of Respiratory Medicine

Transforming Clinical Practices with Expert Reviews
Publisher: TAYLOR & FRANCIS LTDISSN: 1747-6348Frequency: 6 issues/year

Expert Review of Respiratory Medicine is a leading journal published by Taylor & Francis Ltd, dedicated to advancing the field of respiratory medicine through evidence-based research and comprehensive reviews. With a robust ISSN of 1747-6348 and an E-ISSN of 1747-6356, the journal disseminates essential insights into pulmonary and respiratory health, ranking an impressive #33 in Medicine - Pulmonary and Respiratory Medicine on Scopus, reflecting its significant contribution to this discipline. Established in 2007 and extending its reach through 2024, Expert Review of Respiratory Medicine serves as a crucial resource for professionals and researchers dedicated to improving respiratory health outcomes. Though not designated as an open-access journal, its impactful articles are pivotal in shaping clinical practices and guiding future research in respiratory medicine and related fields, including public health and immunology. By engaging with this journal, readers can stay abreast of the latest developments and critically evaluate advancements in respiratory care.